ArticleAnnals of the rheumatic diseases2024

Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS.

Kader Cetin Gedik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.